Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 82

1.

Targeting the Senescence-Overriding Cooperative Activity of Structurally Unrelated H3K9 Demethylases in Melanoma.

Yu Y, Schleich K, Yue B, Ji S, Lohneis P, Kemper K, Silvis MR, Qutob N, van Rooijen E, Werner-Klein M, Li L, Dhawan D, Meierjohann S, Reimann M, Elkahloun A, Treitschke S, Dörken B, Speck C, Mallette FA, Zon LI, Holmen SL, Peeper DS, Samuels Y, Schmitt CA, Lee S.

Cancer Cell. 2018 Apr 9;33(4):785. doi: 10.1016/j.ccell.2018.03.009. No abstract available.

PMID:
29634951
2.

Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors.

Azimi A, Caramuta S, Seashore-Ludlow B, Boström J, Robinson JL, Edfors F, Tuominen R, Kemper K, Krijgsman O, Peeper DS, Nielsen J, Hansson J, Egyhazi Brage S, Altun M, Uhlen M, Maddalo G.

Mol Syst Biol. 2018 Mar 5;14(3):e7858. doi: 10.15252/msb.20177858.

3.

Targeting the Senescence-Overriding Cooperative Activity of Structurally Unrelated H3K9 Demethylases in Melanoma.

Yu Y, Schleich K, Yue B, Ji S, Lohneis P, Kemper K, Silvis MR, Qutob N, van Rooijen E, Werner-Klein M, Li L, Dhawan D, Meierjohann S, Reimann M, Elkahloun A, Treitschke S, Dörken B, Speck C, Mallette FA, Zon LI, Holmen SL, Peeper DS, Samuels Y, Schmitt CA, Lee S.

Cancer Cell. 2018 Feb 12;33(2):322-336.e8. doi: 10.1016/j.ccell.2018.01.002. Erratum in: Cancer Cell. 2018 Apr 9;33(4):785.

4.

Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors.

Boshuizen J, Koopman LA, Krijgsman O, Shahrabi A, van den Heuvel EG, Ligtenberg MA, Vredevoogd DW, Kemper K, Kuilman T, Song JY, Pencheva N, Mortensen JT, Foppen MG, Rozeman EA, Blank CU, Janmaat ML, Satijn D, Breij ECW, Peeper DS, Parren PWHI.

Nat Med. 2018 Feb;24(2):203-212. doi: 10.1038/nm.4472. Epub 2018 Jan 15.

PMID:
29334371
5.

PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models.

Meehan TF, Conte N, Goldstein T, Inghirami G, Murakami MA, Brabetz S, Gu Z, Wiser JA, Dunn P, Begley DA, Krupke DM, Bertotti A, Bruna A, Brush MH, Byrne AT, Caldas C, Christie AL, Clark DA, Dowst H, Dry JR, Doroshow JH, Duchamp O, Evrard YA, Ferretti S, Frese KK, Goodwin NC, Greenawalt D, Haendel MA, Hermans E, Houghton PJ, Jonkers J, Kemper K, Khor TO, Lewis MT, Lloyd KCK, Mason J, Medico E, Neuhauser SB, Olson JM, Peeper DS, Rueda OM, Seong JK, Trusolino L, Vinolo E, Wechsler-Reya RJ, Weinstock DM, Welm A, Weroha SJ, Amant F, Pfister SM, Kool M, Parkinson H, Butte AJ, Bult CJ.

Cancer Res. 2017 Nov 1;77(21):e62-e66. doi: 10.1158/0008-5472.CAN-17-0582.

PMID:
29092942
6.

Cancer drug addiction is relayed by an ERK2-dependent phenotype switch.

Kong X, Kuilman T, Shahrabi A, Boshuizen J, Kemper K, Song JY, Niessen HWM, Rozeman EA, Geukes Foppen MH, Blank CU, Peeper DS.

Nature. 2017 Oct 12;550(7675):270-274. doi: 10.1038/nature24037. Epub 2017 Oct 4.

7.

Massive reshaping of genome-nuclear lamina interactions during oncogene-induced senescence.

Lenain C, de Graaf CA, Pagie L, Visser NL, de Haas M, de Vries SS, Peric-Hupkes D, van Steensel B, Peeper DS.

Genome Res. 2017 Oct;27(10):1634-1644. doi: 10.1101/gr.225763.117. Epub 2017 Sep 15.

8.

Vemurafenib plus cobimetinib in unresectable stage IIIc or stage IV melanoma: response monitoring and resistance prediction with positron emission tomography and tumor characteristics (REPOSIT): study protocol of a phase II, open-label, multicenter study.

van der Hiel B, Haanen JBAG, Stokkel MPM, Peeper DS, Jimenez CR, Beijnen JH, van de Wiel BA, Boellaard R, van den Eertwegh AJM; REPOSIT study group.

BMC Cancer. 2017 Sep 15;17(1):649. doi: 10.1186/s12885-017-3626-5.

9.

Interrogating open issues in cancer medicine with patient-derived xenografts.

Byrne AT, Alférez DG, Amant F, Annibali D, Arribas J, Biankin AV, Bruna A, Budinská E, Caldas C, Chang DK, Clarke RB, Clevers H, Coukos G, Dangles-Marie V, Eckhardt SG, Gonzalez-Suarez E, Hermans E, Hidalgo M, Jarzabek MA, de Jong S, Jonkers J, Kemper K, Lanfrancone L, Mælandsmo GM, Marangoni E, Marine JC, Medico E, Norum JH, Palmer HG, Peeper DS, Pelicci PG, Piris-Gimenez A, Roman-Roman S, Rueda OM, Seoane J, Serra V, Soucek L, Vanhecke D, Villanueva A, Vinolo E, Bertotti A, Trusolino L.

Nat Rev Cancer. 2017 Sep 15;17(10):632. doi: 10.1038/nrc.2017.85. [Epub ahead of print]

PMID:
28912576
10.

Phenotypic diversity drives paracrine drug tolerance.

Kuilman T, Peeper DS.

EMBO Mol Med. 2017 Aug;9(8):987-989. doi: 10.15252/emmm.201707956. No abstract available.

11.

Systematic functional perturbations uncover a prognostic genetic network driving human breast cancer.

Gallenne T, Ross KN, Visser NL, Salony, Desmet CJ, Wittner BS, Wessels LFA, Ramaswamy S, Peeper DS.

Oncotarget. 2017 Mar 15;8(13):20572-20587. doi: 10.18632/oncotarget.16244.

12.

Fatty acid 16:4(n-3) stimulates a GPR120-induced signaling cascade in splenic macrophages to promote chemotherapy resistance.

Houthuijzen JM, Oosterom I, Hudson BD, Hirasawa A, Daenen LGM, McLean CM, Hansen SVF, van Jaarsveld MTM, Peeper DS, Jafari Sadatmand S, Roodhart JML, van de Lest CHA, Ulven T, Ishihara K, Milligan G, Voest EE.

FASEB J. 2017 May;31(5):2195-2209. doi: 10.1096/fj.201601248R. Epub 2017 Feb 9.

13.

Interrogating open issues in cancer precision medicine with patient-derived xenografts.

Byrne AT, Alférez DG, Amant F, Annibali D, Arribas J, Biankin AV, Bruna A, Budinská E, Caldas C, Chang DK, Clarke RB, Clevers H, Coukos G, Dangles-Marie V, Eckhardt SG, Gonzalez-Suarez E, Hermans E, Hidalgo M, Jarzabek MA, de Jong S, Jonkers J, Kemper K, Lanfrancone L, Mælandsmo GM, Marangoni E, Marine JC, Medico E, Norum JH, Palmer HG, Peeper DS, Pelicci PG, Piris-Gimenez A, Roman-Roman S, Rueda OM, Seoane J, Serra V, Soucek L, Vanhecke D, Villanueva A, Vinolo E, Bertotti A, Trusolino L.

Nat Rev Cancer. 2017 Apr;17(4):254-268. doi: 10.1038/nrc.2016.140. Epub 2017 Jan 20. Review. Erratum in: Nat Rev Cancer. 2017 Sep 15;:.

14.

Integrated in vivo genetic and pharmacologic screening identifies co-inhibition of EGRF and ROCK as a potential treatment regimen for triple-negative breast cancer.

Iskit S, Lieftink C, Halonen P, Shahrabi A, Possik PA, Beijersbergen RL, Peeper DS.

Oncotarget. 2016 Jul 12;7(28):42859-42872. doi: 10.18632/oncotarget.10230.

15.

BRAF(V600E) Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived Xenografts.

Kemper K, Krijgsman O, Kong X, Cornelissen-Steijger P, Shahrabi A, Weeber F, van der Velden DL, Bleijerveld OB, Kuilman T, Kluin RJC, Sun C, Voest EE, Ju YS, Schumacher TNM, Altelaar AFM, McDermott U, Adams DJ, Blank CU, Haanen JB, Peeper DS.

Cell Rep. 2016 Jun 28;16(1):263-277. doi: 10.1016/j.celrep.2016.05.064. Epub 2016 Jun 16.

16.

MITF: More Interesting Traits, Folks!

Kemper K, Krijgsman O, Peeper DS.

Pigment Cell Melanoma Res. 2016 May;29(3):263-5. doi: 10.1111/pcmr.12476. Epub 2016 Mar 31. No abstract available.

PMID:
26999069
17.

Fra-1 is a key driver of colon cancer metastasis and a Fra-1 classifier predicts disease-free survival.

Iskit S, Schlicker A, Wessels L, Peeper DS.

Oncotarget. 2015 Dec 22;6(41):43146-61. doi: 10.18632/oncotarget.6454.

18.

Preserved genetic diversity in organoids cultured from biopsies of human colorectal cancer metastases.

Weeber F, van de Wetering M, Hoogstraat M, Dijkstra KK, Krijgsman O, Kuilman T, Gadellaa-van Hooijdonk CG, van der Velden DL, Peeper DS, Cuppen EP, Vries RG, Clevers H, Voest EE.

Proc Natl Acad Sci U S A. 2015 Oct 27;112(43):13308-11. doi: 10.1073/pnas.1516689112. Epub 2015 Oct 12.

19.

Autophagy-mediated degradation of nuclear envelope proteins during oncogene-induced senescence.

Lenain C, Gusyatiner O, Douma S, van den Broek B, Peeper DS.

Carcinogenesis. 2015 Nov;36(11):1263-74. doi: 10.1093/carcin/bgv124. Epub 2015 Sep 8.

PMID:
26354777
20.

PhosphoPath: Visualization of Phosphosite-centric Dynamics in Temporal Molecular Networks.

Raaijmakers LM, Giansanti P, Possik PA, Mueller J, Peeper DS, Heck AJ, Altelaar AF.

J Proteome Res. 2015 Oct 2;14(10):4332-41. doi: 10.1021/acs.jproteome.5b00529. Epub 2015 Sep 8.

PMID:
26317507
21.

Intra- and inter-tumor heterogeneity in a vemurafenib-resistant melanoma patient and derived xenografts.

Kemper K, Krijgsman O, Cornelissen-Steijger P, Shahrabi A, Weeber F, Song JY, Kuilman T, Vis DJ, Wessels LF, Voest EE, Schumacher TN, Blank CU, Adams DJ, Haanen JB, Peeper DS.

EMBO Mol Med. 2015 Sep;7(9):1104-18. doi: 10.15252/emmm.201404914.

22.

Signal Transduction Reaction Monitoring Deciphers Site-Specific PI3K-mTOR/MAPK Pathway Dynamics in Oncogene-Induced Senescence.

de Graaf EL, Kaplon J, Mohammed S, Vereijken LA, Duarte DP, Redondo Gallego L, Heck AJ, Peeper DS, Altelaar AF.

J Proteome Res. 2015 Jul 2;14(7):2906-14. doi: 10.1021/acs.jproteome.5b00236. Epub 2015 Jun 2.

PMID:
26011226
23.

CopywriteR: DNA copy number detection from off-target sequence data.

Kuilman T, Velds A, Kemper K, Ranzani M, Bombardelli L, Hoogstraat M, Nevedomskaya E, Xu G, de Ruiter J, Lolkema MP, Ylstra B, Jonkers J, Rottenberg S, Wessels LF, Adams DJ, Peeper DS, Krijgsman O.

Genome Biol. 2015 Feb 27;16:49. doi: 10.1186/s13059-015-0617-1.

24.

Cooperative induction of apoptosis in NRAS mutant melanoma by inhibition of MEK and ROCK.

Vogel CJ, Smit MA, Maddalo G, Possik PA, Sparidans RW, van der Burg SH, Verdegaal EM, Heck AJ, Samatar AA, Beijnen JH, Altelaar AF, Peeper DS.

Pigment Cell Melanoma Res. 2015 May;28(3):307-17. doi: 10.1111/pcmr.12364. Epub 2015 Apr 6.

PMID:
25728708
25.

ROCK1 is a potential combinatorial drug target for BRAF mutant melanoma.

Smit MA, Maddalo G, Greig K, Raaijmakers LM, Possik PA, van Breukelen B, Cappadona S, Heck AJ, Altelaar AF, Peeper DS.

Mol Syst Biol. 2014 Dec 23;10:772. doi: 10.15252/msb.20145450.

26.

Detailed imaging and genetic analysis reveal a secondary BRAF(L505H) resistance mutation and extensive intrapatient heterogeneity in metastatic BRAF mutant melanoma patients treated with vemurafenib.

Hoogstraat M, Gadellaa-van Hooijdonk CG, Ubink I, Besselink NJ, Pieterse M, Veldhuis W, van Stralen M, Meijer EF, Willems SM, Hadders MA, Kuilman T, Krijgsman O, Peeper DS, Koudijs MJ, Cuppen E, Voest EE, Lolkema MP.

Pigment Cell Melanoma Res. 2015 May;28(3):318-23. doi: 10.1111/pcmr.12347. Epub 2015 Jan 7.

PMID:
25515853
27.

Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma.

Müller J, Krijgsman O, Tsoi J, Robert L, Hugo W, Song C, Kong X, Possik PA, Cornelissen-Steijger PD, Geukes Foppen MH, Kemper K, Goding CR, McDermott U, Blank C, Haanen J, Graeber TG, Ribas A, Lo RS, Peeper DS.

Nat Commun. 2014 Dec 15;5:5712. doi: 10.1038/ncomms6712.

28.

Parallel in vivo and in vitro melanoma RNAi dropout screens reveal synthetic lethality between hypoxia and DNA damage response inhibition.

Possik PA, Müller J, Gerlach C, Kenski JC, Huang X, Shahrabi A, Krijgsman O, Song JY, Smit MA, Gerritsen B, Lieftink C, Kemper K, Michaut M, Beijersbergen RL, Wessels L, Schumacher TN, Peeper DS.

Cell Rep. 2014 Nov 20;9(4):1375-86. doi: 10.1016/j.celrep.2014.10.024. Epub 2014 Nov 6.

29.

Phenotype switching: tumor cell plasticity as a resistance mechanism and target for therapy.

Kemper K, de Goeje PL, Peeper DS, van Amerongen R.

Cancer Res. 2014 Nov 1;74(21):5937-41. doi: 10.1158/0008-5472.CAN-14-1174. Epub 2014 Oct 15. Review.

30.

Cancer drug resistance: old concept, novel solutions required.

Peeper DS.

Mol Oncol. 2014 Sep 12;8(6):1064-6. doi: 10.1016/j.molonc.2014.07.026. Epub 2014 Aug 7. No abstract available.

31.

Phosphoproteome dynamics in onset and maintenance of oncogene-induced senescence.

de Graaf EL, Kaplon J, Zhou H, Heck AJ, Peeper DS, Altelaar AF.

Mol Cell Proteomics. 2014 Aug;13(8):2089-100. doi: 10.1074/mcp.M113.035436. Epub 2014 Jun 24.

32.

Near-genomewide RNAi screening for regulators of BRAF(V600E) -induced senescence identifies RASEF, a gene epigenetically silenced in melanoma.

Kaplon J, Hömig-Hölzel C, Gao L, Meissl K, Verdegaal EM, van der Burg SH, van Doorn R, Peeper DS.

Pigment Cell Melanoma Res. 2014 Jul;27(4):640-52. doi: 10.1111/pcmr.12248. Epub 2014 May 14.

PMID:
24703243
33.

A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence.

Kaplon J, Zheng L, Meissl K, Chaneton B, Selivanov VA, Mackay G, van der Burg SH, Verdegaal EM, Cascante M, Shlomi T, Gottlieb E, Peeper DS.

Nature. 2013 Jun 6;498(7452):109-12. doi: 10.1038/nature12154. Epub 2013 May 19.

PMID:
23685455
34.

Genome-wide promoter methylation analysis identifies epigenetic silencing of MAPK13 in primary cutaneous melanoma.

Gao L, Smit MA, van den Oord JJ, Goeman JJ, Verdegaal EM, van der Burg SH, Stas M, Beck S, Gruis NA, Tensen CP, Willemze R, Peeper DS, van Doorn R.

Pigment Cell Melanoma Res. 2013 Jul;26(4):542-54. doi: 10.1111/pcmr.12096. Epub 2013 Apr 17.

PMID:
23590314
35.

Identification of a pharmacologically tractable Fra-1/ADORA2B axis promoting breast cancer metastasis.

Desmet CJ, Gallenne T, Prieur A, Reyal F, Visser NL, Wittner BS, Smit MA, Geiger TR, Laoukili J, Iskit S, Rodenko B, Zwart W, Evers B, Horlings H, Ajouaou A, Zevenhoven J, van Vliet M, Ramaswamy S, Wessels LF, Peeper DS.

Proc Natl Acad Sci U S A. 2013 Mar 26;110(13):5139-44. doi: 10.1073/pnas.1222085110. Epub 2013 Mar 12.

36.

Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis.

Vredeveld LC, Possik PA, Smit MA, Meissl K, Michaloglou C, Horlings HM, Ajouaou A, Kortman PC, Dankort D, McMahon M, Mooi WJ, Peeper DS.

Genes Dev. 2012 May 15;26(10):1055-69. doi: 10.1101/gad.187252.112. Epub 2012 May 1.

37.

If you can't beat me, join me: collaborating oncogenes circumventing senescence and causing cancer.

Possik PA, Peeper DS.

Pigment Cell Melanoma Res. 2011 Aug;24(4):586-7. No abstract available.

PMID:
22489324
38.

Ageing: Old cells under attack.

Peeper DS.

Nature. 2011 Nov 9;479(7372):186-7. doi: 10.1038/479186a. No abstract available.

PMID:
22071762
39.

Oncogene-induced senescence and melanoma: where do we stand?

Peeper DS.

Pigment Cell Melanoma Res. 2011 Dec;24(6):1107-11. doi: 10.1111/j.1755-148X.2011.00933.x. Review.

PMID:
22018309
40.

Evidence of oncogene-induced senescence in thyroid carcinogenesis.

Vizioli MG, Possik PA, Tarantino E, Meissl K, Borrello MG, Miranda C, Anania MC, Pagliardini S, Seregni E, Pierotti MA, Pilotti S, Peeper DS, Greco A.

Endocr Relat Cancer. 2011 Dec 1;18(6):743-57. doi: 10.1530/ERC-11-0240. Print 2011 Dec.

41.

C/EBPβ: lost beyond translation.

Peeper DS.

EMBO J. 2011 Sep 14;30(18):3663-4. doi: 10.1038/emboj.2011.288. No abstract available.

42.

Zeb1 is required for TrkB-induced epithelial-mesenchymal transition, anoikis resistance and metastasis.

Smit MA, Peeper DS.

Oncogene. 2011 Sep 1;30(35):3735-44. doi: 10.1038/onc.2011.96. Epub 2011 Apr 11.

PMID:
21478908
43.

Antagonistic TSC22D1 variants control BRAF(E600)-induced senescence.

Hömig-Hölzel C, van Doorn R, Vogel C, Germann M, Cecchini MG, Verdegaal E, Peeper DS.

EMBO J. 2011 May 4;30(9):1753-65. doi: 10.1038/emboj.2011.95. Epub 2011 Mar 29.

44.

Functional characterization of human cancer-derived TRKB mutations.

Geiger TR, Song JY, Rosado A, Peeper DS.

PLoS One. 2011 Feb 17;6(2):e16871. doi: 10.1371/journal.pone.0016871.

45.

The essence of senescence.

Kuilman T, Michaloglou C, Mooi WJ, Peeper DS.

Genes Dev. 2010 Nov 15;24(22):2463-79. doi: 10.1101/gad.1971610. Review.

46.
47.

Impact papers on aging in 2009.

Blagosklonny MV, Campisi J, Sinclair DA, Bartke A, Blasco MA, Bonner WM, Bohr VA, Brosh RM Jr, Brunet A, Depinho RA, Donehower LA, Finch CE, Finkel T, Gorospe M, Gudkov AV, Hall MN, Hekimi S, Helfand SL, Karlseder J, Kenyon C, Kroemer G, Longo V, Nussenzweig A, Osiewacz HD, Peeper DS, Rando TA, Rudolph KL, Sassone-Corsi P, Serrano M, Sharpless NE, Skulachev VP, Tilly JL, Tower J, Verdin E, Vijg J.

Aging (Albany NY). 2010 Mar;2(3):111-21. Epub 2010 Mar 23. Review.

48.

PICS-ure this: prosenescence therapy?

Peeper DS.

Cancer Cell. 2010 Mar 16;17(3):219-20. doi: 10.1016/j.ccr.2010.02.028.

49.

Functional identification of LRF as an oncogene that bypasses RASV12-induced senescence via upregulation of CYCLIN E.

Vredeveld LC, Rowland BD, Douma S, Bernards R, Peeper DS.

Carcinogenesis. 2010 Feb;31(2):201-7. doi: 10.1093/carcin/bgp296. Epub 2009 Nov 25.

PMID:
19942610
50.

Metastasis mechanisms.

Geiger TR, Peeper DS.

Biochim Biophys Acta. 2009 Dec;1796(2):293-308. doi: 10.1016/j.bbcan.2009.07.006. Epub 2009 Aug 14. Review.

PMID:
19683560

Supplemental Content

Loading ...
Support Center